Abstract | AIM: To evaluate effects of tiklid and aspirin on hemostasis, antithrombogenic activity of vascular wall in patients with unstable angina (UA). MATERIAL AND METHODS: An open randomized trial enrolled 30 UA patients given tiklid (n = 16) or aspirin (n = 14). Hemostasis, platelet aggregation, antithrombogenic activity of the vascular wall were examined on the treatment day 1 and 20. The response was assessed by the number of anginal attacks, dose of nitroglycerine, data of Holter monitoring. RESULTS: Tiklid was more effective than aspirin in UA patients as it by the treatment day 20 lowered platelet aggregation more, higher elevated anticoagulation potential of the blood and vessels, and stronger activated fibrinolytic hemostasis. CONCLUSION: Compared to aspirin, tiklid is more potent antiaggregant, has greater effect on antithrombogenic properties of the vascular wall.
|
Authors | A P Rebrov, I V Voskoboĭ |
Journal | Terapevticheskii arkhiv
(Ter Arkh)
Vol. 73
Issue 12
Pg. 25-9
( 2001)
ISSN: 0040-3660 [Print] Russia (Federation) |
Vernacular Title | Sravnitel'noe izuchenie éffektivnosti tiklida i aspirina u bol'nykh nestabil'noĭ stenokardieĭ. |
PMID | 11858103
(Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Fibrinolytic Agents
- Platelet Aggregation Inhibitors
- Ticlopidine
- Aspirin
|
Topics |
- Angina, Unstable
(blood, drug therapy)
- Aspirin
(metabolism, therapeutic use)
- Blood Coagulation
(drug effects)
- Endothelium, Vascular
(drug effects, metabolism)
- Female
- Fibrinolytic Agents
(therapeutic use)
- Humans
- Male
- Middle Aged
- Platelet Aggregation Inhibitors
(therapeutic use)
- Prothrombin Time
- Ticlopidine
(therapeutic use)
|